250 related articles for article (PubMed ID: 24134421)
1. Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective.
Girard N
Expert Rev Anticancer Ther; 2013 Oct; 13(10):1193-206. PubMed ID: 24134421
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer.
Reckamp KL
Cancer Lett; 2012 Aug; 321(2):101-9. PubMed ID: 22306704
[TBL] [Abstract][Full Text] [Related]
3. Nintedanib in non-small cell lung cancer: from preclinical to approval.
Caglevic C; Grassi M; Raez L; Listi A; Giallombardo M; Bustamante E; Gil-Bazo I; Rolfo C
Ther Adv Respir Dis; 2015 Aug; 9(4):164-72. PubMed ID: 25855060
[TBL] [Abstract][Full Text] [Related]
4. Emerging antiangiogenic therapies for non-small-cell lung cancer.
Blakely C; Jahan T
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1607-18. PubMed ID: 21999134
[TBL] [Abstract][Full Text] [Related]
5. [Antiangiogenic agents: current limits in thoracic oncology].
Dansin E; Lauridant G; Chahine B
Bull Cancer; 2012 Nov; 99(11):1083-91. PubMed ID: 23113985
[TBL] [Abstract][Full Text] [Related]
6. Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer.
Bertino EM; Otterson GA
Lung Cancer; 2010 Dec; 70(3):233-46. PubMed ID: 20888062
[TBL] [Abstract][Full Text] [Related]
7. Targeting tumor neovasculature in non-small-cell lung cancer.
Pallis AG; Syrigos KN
Crit Rev Oncol Hematol; 2013 May; 86(2):130-42. PubMed ID: 23159217
[TBL] [Abstract][Full Text] [Related]
8. BIBF 1120 for the treatment of non-small cell lung cancer.
Reck M
Expert Opin Investig Drugs; 2010 Jun; 19(6):789-94. PubMed ID: 20465363
[TBL] [Abstract][Full Text] [Related]
9. Antivascular agents for non-small-cell lung cancer: current status and future directions.
Amir E; Mandoky L; Blackhall F; Thatcher N; Klepetko W; Ankersmit HJ; Reza Hoda MA; Ostoros G; Dank M; Dome B
Expert Opin Investig Drugs; 2009 Nov; 18(11):1667-86. PubMed ID: 19877762
[TBL] [Abstract][Full Text] [Related]
10. [Angiogenesis and neoangiogenesis--the role in lung cancer and other tumors].
Swidzińska E; Naumnik W; Chyczewska E
Pneumonol Alergol Pol; 2006; 74(4):414-20. PubMed ID: 17427152
[No Abstract] [Full Text] [Related]
11. Novel angiogenesis inhibitors in nonsmall cell lung cancer.
Reinmuth N; Heigener D; Reck M
Curr Opin Oncol; 2015 Mar; 27(2):79-86. PubMed ID: 25602682
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic therapy in nonsmall cell lung cancer.
Gutierrez M; Giaccone G
Curr Opin Oncol; 2008 Mar; 20(2):176-82. PubMed ID: 18300767
[TBL] [Abstract][Full Text] [Related]
13. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
Manegold C
Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
[TBL] [Abstract][Full Text] [Related]
14. Ongoing trials with bevacizumab and other antiangiogenic agents in lung cancer.
Dowlati A
Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S71-5. PubMed ID: 21885002
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer.
Nguewa PA; Calvo A; Pullamsetti SS; Banat GA; Grimminger F; Savai R
Expert Opin Investig Drugs; 2011 Jan; 20(1):61-74. PubMed ID: 21142806
[TBL] [Abstract][Full Text] [Related]
16. [Anti-angiogenic factors in thoracic oncology: successes, failures and prospects].
Marco S; Tomasini P; Greillier L; Barlesi F
Rev Mal Respir; 2011 Dec; 28(10):1216-29. PubMed ID: 22152931
[TBL] [Abstract][Full Text] [Related]
17. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
Janning M; Loges S
Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
[TBL] [Abstract][Full Text] [Related]
18. An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.
Pilotto S; Novello S; Peretti U; Kinspergher S; Ciuffreda L; Milella M; Carbognin L; Vavalà T; Ferrara R; Caccese M; Tortora G; Bria E
Expert Opin Investig Drugs; 2015; 24(9):1143-61. PubMed ID: 26065529
[TBL] [Abstract][Full Text] [Related]
19. Current and future strategies for antiangiogenic agents in non-small-cell lung cancer.
Herbst RS
Clin Lung Cancer; 2008 Mar; 9 Suppl 2():S50. PubMed ID: 21884998
[No Abstract] [Full Text] [Related]
20. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
